Segment & Geographic Data Quant-Grade Normalized (live API) API & CSV Delivery

Acorda Therapeutics Inc's Business Segments

Acorda Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.

Segment Data As of FY

Reportable Segments

Per the company's own filing, this quarter

Largest Segment

Total Revenue

$ 20

Consolidated, this quarter

Regions Reported

Geographic regions, this quarter

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/ACORQ/segments                    

                        https://api.csimarket.com/api/v1/companies/ACORQ/geographic                    

                        https://api.csimarket.com/api/v1/companies/ACORQ/exposure                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Acorda Therapeutics Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.

Revenue by Product & Service Category - FY

Product88.1%
Ampyra56.7%
Inbrija23.3%
Royalty11.8%
Inbrija EXUS8.2%
License Revenue0.1%
License0.1%

Revenue by Product & Service Category - FY

Category	Period	Revenue (Millions)	% of Total
Product	FY	$ 18	88.1%
Ampyra	FY	$ 11	56.7%
Inbrija	FY	$ 5	23.3%

Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.

4 more categories available

Description of Acorda Therapeutics Inc

Acorda Therapeutics, Inc. is a biopharmaceutical company developing therapies for neurological disorders. The company markets Inbrija (levodopa inhalation powder), approved in the U.S. for the intermittent treatment of OFF episodes in Parkinson's disease patients treated with carbidopa/levodopa. Inbrija uses Acorda's ARCUS pulmonary delivery technology and is intended for as-needed use. Acorda also markets Ampyra and Fampyra, with Fampyra commercialized outside the U.S. through collaborations and distribution agreements. The company faces risks including Chapter 11 bankruptcy proceedings, maintaining supplier and customer relationships, competition from generic products, reliance on third-party manufacturers, reimbursement challenges, and regulatory compliance. Acorda holds registered trademarks for Acorda Therapeutics, Ampyra, Inbrija, ARCUS, and Fampyra in the U.S. and other jurisdictions. The company is engaged in efforts to manage its operations, including potential restructuring and collaborations to support global commercialization and supply of its products.